SCHEMBL24124285

SCHEMBL24124285

Nc1ccc(CC(=O)Nc2cccc(C(=O)Nc3ccc(S(=O)(=O)Nc4ccccc4)cc3)c2)cc1

nearest known ligand 0.60

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 10/20 0.56
GPR27 Q9NS67 1/20 0.55
MEN1 O00255 7/20 0.55
MAPT P10636 2/20 0.54
HTT P42858 2/20 0.54
CYP1A2 P05177 1/20 0.54
CYP3A4 P08684 1/20 0.54
CYP2D6 P10635 1/20 0.54
CYP2C9 P11712 1/20 0.54
CYP2C19 P33261 1/20 0.54
RECQL P46063 1/20 0.54
LMNA P02545 1/20 0.54
KDM4E B2RXH2 1/20 0.54
PRMT1 Q99873 1/20 0.53
HDAC1 Q13547 1/20 0.52
HDAC8 Q9BY41 1/20 0.52
ALDH1A1 P00352 1/20 0.51
POLB P06746 1/20 0.51
HPGD P15428 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24124920 0.93 KMT2A (0.65) KMT2AGPR27MEN1MAPTHTT
SCHEMBL24124292 0.91 KMT2A (0.55) KMT2AGPR27MEN1MAPTHTT
SCHEMBL24124265 0.88 KMT2A (0.67) KMT2AGPR27MEN1MAPTHTT
SCHEMBL25921932 0.86 MAPT (0.57) KMT2AGPR27MEN1MAPTHTT
SCHEMBL30522656 0.85 KMT2A (0.65) KMT2AGPR27MEN1MAPTHTT
SCHEMBL24124279 0.85 KMT2A (0.65) KMT2AGPR27MEN1MAPTHTT
SCHEMBL30522648 0.83 MAPT (0.56) KMT2AGPR27MEN1MAPTHTT
SCHEMBL25324493 0.83 MAPT (0.56) KMT2AGPR27MEN1MAPTHTT
SCHEMBL25323225 0.82 MAPT (0.58) KMT2AGPR27MEN1MAPTHTT
SCHEMBL30522641 0.82 MAPT (0.58) KMT2AGPR27MEN1MAPTHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230242496-A1 SOX11 INHIBITORS FOR TREATING MANTLE CELL LYMPHOMA ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) 2023-08-03 US disclosed
US-20230242496-A1 SOX11 INHIBITORS FOR TREATING MANTLE CELL LYMPHOMA ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) 2023-08-03 US disclosed
WO-2021257544-A1 SOX11 INHIBITORS FOR TREATING MANTLE CELL LYMPHOMA ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) 2021-12-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230242496-A1 SOX11 INHIBITORS FOR TREATING MANTLE CELL LYMPHOMA BCL6, SOX18, BCL3 KMT2A 578/4885GPR27 1850/4885MEN1 2558/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.